小細胞肺癌治療市場－全球產業規模、佔有率、趨勢、機會及預測（依治療類型、藥物類型、通路、地區及競爭格局分類，2021-2031年）

全球小細胞肺癌治療市場預計將從 2025 年的 69.1 億美元大幅成長至 2031 年的 127.5 億美元，複合年成長率達 10.75%。

該領域專注於研發和商業化藥物干預措施，包括化療、免疫療法和標靶藥物，旨在對抗這種侵襲性神經內分泌癌症。推動這一成長的關鍵因素包括全球吸煙率上升和人口老化，這兩者都導致急需治療的患者群體不斷擴大。此外，免疫查核點抑制劑的頻繁核准正在重新定義治療標準，也推動了市場的發展。國際癌症研究機構 (IARC) 的數據顯示，在最新的報告期間內，2025 年全球新增小細胞肺癌病例將約佔 26.8 萬例。

儘管市場有所成長，但仍面臨許多障礙，包括先進免疫療法的高成本，這限制了醫療預算有限的開發中國家患者獲得治療的機會。嚴格的報銷政策和醫療系統沉重的財政負擔往往阻礙了這些現代治療方法的廣泛應用，導致主要新興市場的收入成長停滯不前。因此，儘管臨床對有效治療方法的需求依然旺盛，但經濟障礙仍阻礙著這些治療創新成果的全面商業性化。

市場促進因素

先進免疫療法和標靶藥物的引入和廣泛應用正在從根本上改變小細胞肺癌的治療模式。監管機構正擴大核准針對特定生物路徑的創新治療方法，為那些病情已超出標準化療的患者提供新的治療選擇。這種變化的顯著體現是靶向Delta樣配體3的雙特異性T細胞銜接器的出現，這標誌著治療模式與傳統模式的重大轉變。例如，安進公司在2024年5月的新聞稿中宣布，FDA已加速核准IMDELLTRA（tallatamab-dlle）用於治療晚期小細胞肺癌。此核准是基於臨床試驗結果，結果顯示IMDELLTRA在晚期患者中的中位緩解持續時間為9.7個月，這一突破性成果揭示了一種全新的作用機制，並將促進其在臨床上的進一步應用。

與這些監管方面的成就一致，市場正受到旨在拓展腫瘤產品組合的大規模企業投資和策略性收購的推動。製藥公司正積極尋求併購，以確保獲得前景廣闊的在研療法，特別是那些利用免疫活化和精準腫瘤標靶化技術的療法。正如默克在2024年1月的新聞稿中所宣布的，該公司同意以約6.8億美元的價格收購Harpoon Therapeutics，以將新型T細胞銜接器納入其開發平臺。這些策略性財務措施將穩定研發資金，並加速臨床試驗到產品上市的進程。此外，美國癌症協會指出，到2024年，小細胞肺癌將佔所有肺癌病例的10%至15%左右，凸顯了持續治療方法創新的迫切性。

市場挑戰

新型免疫療法的高昂價格是全球小細胞肺癌治療市場的主要阻礙因素。這些高成本構成了廣泛應用的重大經濟障礙，尤其是在醫療資金有限的地區。面對預算限制，各國醫療體系和支付者往往實施嚴格的報銷通訊協定，導致病患無法獲得昂貴的治療。因此，醫療服務提供者常常被迫使用老舊的非專利化療藥物，而非先進的療法，這直接限制了價格敏感地區製藥企業的商機。

近期產業數據顯示，患者負擔能力問題凸顯了這項經濟負擔的影響。根據美國癌症協會（ACS）發布的《2024年報告》，約58%的癌症患者面臨與治療費用和保險自付部分相關的經濟困難。這種經濟壓力限制了能夠負擔這些昂貴治療的患者數量，從而顯著縮小了整體市場規模。最終，臨床需求與較佳治療方法的經濟可行性之間的差距，持續阻礙這些療法的商業性發展。

市場趨勢

免疫療法聯合治療作為標準治療方案的應用範圍正從晚期疾病擴展到包括局限期小細胞肺癌，從而為早期療育創造了新的治療模式。這一趨勢是將免疫查核點抑制劑與放射線治療合併使用，以提高潛在可治癒患者的存活率。 2024年6月，Astra Zeneca在ASCO會議上公佈了其III期ADRIATIC試驗的結果，結果顯示，在放射線治療後病情未進展的局限期患者中，Durvalumab與安慰劑相比，死亡風險降低了27%。免疫療法適應症的擴展標誌著該市場的一個重要轉折點，為近幾十年來鮮有治療突破的患者群體確立了新的治療標準。

同時，針對 DLL3 的抗體藥物複合體(ADC) 的興起，正在建立一種與雙特異性 T 細胞銜接器作用機制不同的強效細胞毒性治療方法。與活化免疫系統的治療方法不同，這些偶聯物利用特異性抗體將化療直接遞送至表達Delta的癌細胞，從而有效避免了全身化療中常見的抗藥性問題。 2024 年 9 月，第一三共株式會社公佈了 II 期臨床試驗「IDeate-Lung01」的中期分析結果，報告顯示，伊菲那他單抗德魯替康在 12 mg/kg 劑量組中的確認客觀緩解率達到 54.8%。這項進展表明，抗體藥物複合體作為一種精準標靶治療策略，在先前接受過治療的晚期疾病治療中具有越來越高的可行性。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球小細胞肺癌藥物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依治療方法（免疫療法、標靶治療、化療）
  • 依藥物類型（Atezolizumab、拓樸替康、魯比替定、度伐Durvalumab、胺基甲基葉酸呤製劑、Pembrolizumab）
  • 按分銷管道（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美小細胞肺癌藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲小細胞肺癌藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區小細胞肺癌藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲小細胞肺癌藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美小細胞肺癌藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球小細胞肺癌藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Eli Lilly and Company
• Aurobindo Pharma Limited
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Small Cell Lung Cancer Therapeutics Market is projected to expand significantly, rising from USD 6.91 Billion in 2025 to USD 12.75 Billion by 2031, reflecting a compound annual growth rate of 10.75%. This sector focuses on the creation and sale of pharmaceutical interventions, including chemotherapy, immunotherapies, and targeted agents designed to combat this aggressive neuroendocrine cancer. Key factors propelling this growth include the increasing global prevalence of tobacco use and an aging population, both of which contribute to a larger patient pool requiring immediate care. Additionally, the market is bolstered by frequent regulatory approvals for immune checkpoint inhibitors that are redefining treatment standards. Data from the International Agency for Research on Cancer indicates that in 2025, small-cell carcinoma was responsible for roughly 268,000 new lung cancer cases worldwide during the latest reporting period.

Despite this growth, the market faces significant hurdles due to the high costs of advanced immunotherapeutic regimens, which restrict patient access in developing nations with limited healthcare budgets. Strict reimbursement policies and the substantial financial strain on healthcare systems frequently hinder the widespread uptake of these modern therapies, subsequently stalling revenue progress in critical emerging markets. As a result, although clinical demand for effective treatments remains strong, economic obstacles continue to impede the full commercial realization of these therapeutic innovations.

Market Driver

The introduction and uptake of advanced immunotherapies and targeted agents are fundamentally transforming the treatment framework for small cell lung cancer. Regulatory bodies are increasingly authorizing innovative therapies that focus on specific biological pathways, providing renewed options for patients who have progressed past standard chemotherapy. This evolution is highlighted by the emergence of bispecific T-cell engagers targeting Delta-like ligand 3, representing a major shift from traditional care models. For instance, Amgen reported in a May 2024 press release that the FDA granted accelerated approval to IMDELLTRA (tarlatamab-dlle) following clinical trials that showed a median response duration of 9.7 months in patients with extensive-stage disease, a milestone that validates new mechanisms of action and spurs further clinical adoption.

In parallel with these regulatory achievements, the market is propelled by significant corporate investments and strategic acquisitions designed to broaden oncology portfolios. Pharmaceutical companies are actively engaging in mergers to secure promising investigational drugs, particularly those utilizing immune engagement and precise tumor targeting. As noted in a January 2024 press release, Merck agreed to acquire Harpoon Therapeutics for a total equity value of approximately $680 million to incorporate novel T-cell engagers into their development pipeline. These strategic financial actions ensure a steady flow of capital into research and development, speeding up the journey from clinical trials to the marketplace. Moreover, the American Cancer Society noted in 2024 that small cell lung cancer comprises about 10% to 15% of all lung cancer cases, emphasizing the urgent need for sustained therapeutic innovation.

Market Challenge

The steep prices attached to novel immunotherapeutic regimens serve as a major constraint on the Global Small Cell Lung Cancer Therapeutics Market. These high costs establish formidable economic hurdles that obstruct widespread adoption, especially in areas with restricted healthcare funding. Facing budgetary limitations, national health systems and payers often enforce rigorous reimbursement protocols that either delay or refuse access to costly treatments. Consequently, medical providers are frequently compelled to utilize older, generic chemotherapy alternatives instead of advanced agents, which directly limits potential revenue opportunities for pharmaceutical developers in price-sensitive regions.

The consequences of this financial toxicity are highlighted by recent industry data regarding patient affordability. According to the American Cancer Society's 2024 report, approximately 58 percent of cancer patients experienced financial difficulties related to treatment costs and insurance deductibles. This economic pressure restricts the number of patients able to afford high-value therapies, thereby significantly shrinking the overall market volume. Ultimately, the gap between the clinical necessity for better treatments and their economic feasibility continues to retard the commercial growth of these therapeutics.

Market Trends

The incorporation of immunotherapy combinations as a standard of care is extending beyond extensive-stage disease to include limited-stage small cell lung cancer, creating new treatment models for earlier intervention. This trend entails administering immune checkpoint inhibitors alongside concurrent chemoradiotherapy to enhance survival rates in patients with curative potential. In June 2024, AstraZeneca announced that results from the Phase III ADRIATIC trial presented at ASCO showed that durvalumab reduced the risk of death by 27% compared to placebo in patients with limited-stage disease who had not progressed after chemoradiotherapy. This broadening of immunotherapy indications marks a pivotal market shift, establishing a new care standard for a patient group that has experienced few therapeutic breakthroughs in recent decades.

Concurrently, the rise of DLL3-targeting antibody-drug conjugates is establishing a potent cytotoxic approach that functions differently from bispecific T-cell engagers. Unlike therapies that engage the immune system, these conjugates employ specific antibodies to transport chemotherapy payloads directly to tumor cells expressing Delta-like ligand 3, effectively bypassing resistance issues often seen with systemic chemotherapy. In September 2024, Daiichi Sankyo reported that an interim analysis of the Phase 2 IDeate-Lung01 trial showed ifinatamab deruxtecan achieved a confirmed objective response rate of 54.8% in patients receiving the 12 mg/kg dose. This progress highlights the increasing feasibility of antibody-drug conjugates as a precision-targeted strategy for treating pretreated extensive-stage disease.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Eli Lilly and Company
• Aurobindo Pharma Limited
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.

Report Scope

In this report, the Global Small Cell Lung Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Small Cell Lung Cancer Therapeutics Market, By Therapy Type

• Immunotherapy
• Targeted Therapy
• Chemotherapy

Small Cell Lung Cancer Therapeutics Market, By Drug Type

• Atezolizumab
• Topotecan
• Lurbinectedin
• Durvalumab
• Methotrexate side
• Pembrolizumab

Small Cell Lung Cancer Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Small Cell Lung Cancer Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Small Cell Lung Cancer Therapeutics Market.

Available Customizations:

Global Small Cell Lung Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Small Cell Lung Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Immunotherapy, Targeted Therapy, Chemotherapy)
  • 5.2.2. By Drug Type (Atezolizumab, Topotecan, Lurbinectedin, Durvalumab, Methotrexate side, Pembrolizumab)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Small Cell Lung Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Small Cell Lung Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Small Cell Lung Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Small Cell Lung Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Distribution Channel

7. Europe Small Cell Lung Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Drug Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Small Cell Lung Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Small Cell Lung Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Small Cell Lung Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Small Cell Lung Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Small Cell Lung Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Small Cell Lung Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Small Cell Lung Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Small Cell Lung Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Small Cell Lung Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Small Cell Lung Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Small Cell Lung Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Small Cell Lung Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Small Cell Lung Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Small Cell Lung Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Small Cell Lung Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Distribution Channel

10. South America Small Cell Lung Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Drug Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Small Cell Lung Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Small Cell Lung Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Small Cell Lung Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Small Cell Lung Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Merck & Co., Inc.
• 15.4. Sun Pharmaceutical Industries Ltd.
• 15.5. Lupin Limited
• 15.6. Eli Lilly and Company
• 15.7. Aurobindo Pharma Limited
• 15.8. Bayer AG
• 15.9. Teva Pharmaceutical Industries Ltd.
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer